These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38114758)

  • 41. [Notification of adverse drug events in Brazil: profile of professionals who notify the Brazilian pharmacovigilance system].
    Melo JRR; Duarte EC; Arrais PSD
    Cad Saude Publica; 2021; 37(11):e00237221. PubMed ID: 34816955
    [No Abstract]   [Full Text] [Related]  

  • 42. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions.
    Mulchandani R; Kakkar AK
    Int J Risk Saf Med; 2019; 30(1):33-44. PubMed ID: 30175985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
    de Germay S; Singier A; Salvo F; Pariente A;
    Drug Saf; 2023 Dec; 46(12):1381-1389. PubMed ID: 37926785
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data.
    Grandvuillemin A; Fresse A; Cholle C; Yamani S; Dautriche A;
    Therapie; 2020; 75(4):385-387. PubMed ID: 32402475
    [No Abstract]   [Full Text] [Related]  

  • 47. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An historical overview over Pharmacovigilance.
    Fornasier G; Francescon S; Leone R; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):744-747. PubMed ID: 29948743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Editorial: adverse drug reactions].
    Taegtmeyer AB
    Ther Umsch; 2015 Dec; 72(11-12):667. PubMed ID: 26654808
    [No Abstract]   [Full Text] [Related]  

  • 50. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacovigilance in developing countries (part II): a path forward.
    Elshafie S; Roberti AM; Zaghloul I
    Int J Clin Pharm; 2018 Aug; 40(4):764-768. PubMed ID: 29322474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improving the Safety of Medicines in the European Union: From Signals to Action.
    Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
    Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice.
    Raschi E; La Placa M; Poluzzi E; De Ponti F
    Br J Dermatol; 2021 Mar; 184(3):581-583. PubMed ID: 33184850
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparison of Patient Adverse Drug Reaction Reporting Systems in Nine Selected Countries.
    Worakunphanich W; Youngkong S; Suwankesawong W; Anderson C; Thavorncharoensap M
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457318
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse drug reactions associated with ivermectin use for COVID-19 reported in the World Health Organization's pharmacovigilance database.
    Campillo JT; Faillie JL
    Therapie; 2022; 77(6):747-749. PubMed ID: 35606189
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacovigilance in Russia: current state of affairs, challenges, and prospects.
    Gildeeva G; Belostotsky A
    Curr Med Res Opin; 2017 Dec; 33(12):2161-2166. PubMed ID: 28562116
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advanced analytics - translating registry science into regulatory actions.
    Kemp K; Brun NC; Quartarolo JP
    Expert Opin Drug Saf; 2020 May; 19(5):533-535. PubMed ID: 32125192
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Visualising Patterns Associated with Adverse Drug Reactions in French Forums.
    Allam N; Audeh B; Jaulent MC; Bousquet C
    Stud Health Technol Inform; 2021 May; 281():1110-1111. PubMed ID: 34042861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacovigilance and drug safety: Fair prescribing and clinical research.
    Montastruc JL
    Therapie; 2022; 77(3):261-263. PubMed ID: 35581019
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.